18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors
Authors:
- 1 January 2020
- journal article
- research article
- Published by Elsevier in PET Clinics
- Vol. 15 (1) , 11-22
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council (APP1108050)
This publication has 60 references indexed in Scilit:
- Combination cancer immunotherapies tailored to the tumour microenvironmentNature Reviews Clinical Oncology, 2015
- Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanomaOncoImmunology, 2013
- Tumor immunosurveillance in human cancersCancer and Metastasis Reviews, 2011
- Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel ImmunotherapySeminars in Oncology, 2010
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- PD-1 and PD-1 ligands: from discovery to clinical applicationInternational Immunology, 2007
- RECIST revisited: A review of validation studies on tumour assessmentEuropean Journal of Cancer, 2006